Introduction
Several antibiotics have proved to be valuable adjuncts to the treatment of cholera (Greenough et al., 1964; Carpenter et al., 1966; Lindenbaum et al., 1968) , and tetracycline has been recommended as the antibiotic of choice (Wallace et al., 1968) . Despite its clearly proved usefulness tetracycline is expensive in some countries, and there is some evidence that cholera vibrios may develop resistance to it (Lewis, 1967) . These limitations have prompted a search for an alternative antibacterial agent of equal therapeutic efficacy and lacking these shortcomings. This paper reports our findings in a controlled study comparing tetracycline with furazolidone, a nitrofurantoin derivative, in the treatment of cholera.
Methods and Materials
The study was carried out in April to July 1967 and included 65 male patients over the age of 10 years who gave a history of "rice water" diarrhoea of less than 24 hours' duration without previous antibiotic treatment, and who showed evidence of dehydration and hypotension (systolic blood pressure less than 80 mm. Hg) when admitted to hospital. Data on 49 patients are presented, the remainder being excluded because of failure to identify Vibrio cholerae in the stool (14 patients) or because of technical errors in performance of the study (two patients). Immediately on admission the patient was weighed and placed on a metabolic bed. A brief physical examination was made, a femoral artery blood specimen obtained, and intravenous fluid replacement promptly started. The (Gan and Tija, 1963) and to Mukherjee's type IV phage (Mukherjee et al., 1957) , and being haemagglutininpositive (Barua and Mukherjee, 1963 (Lewis and Sanyal, 1965) .
Results
Historical, physical, and laboratory data for each therapeutic group obtained at admission are compared in Table I . There was no significant difference between groups in regard to any observation when examined by analysis of variance. Stool output during the first six hours, though less in the tetracycline group, did not differ significantly (0.05<P<0.10) from the other groups. V. cholerae, biotype El Tor, Ogawa, was isolated from each case. 
Clinical Course and Vibrio Excretion
The results of treatment are compared in Table II . Total stool volume and duration of diarrhoea were linearly related to the initial six-hour stool output. In the tetracycline group the initial six-hour stool volume was lower than in the other three (0.05<P<0.10). It was assumed that this was a chance occurrence in this group and was unrelated to antibiotic therapy which was begun late in the first six-hour period. It was thought necessary to take this initial difference into consideration in comparing the groups. They were therefore compared by analysis of covariance which corrected for the initial differences between them. Total 
Discussion
The effectiveness of antibiotics as adjuncts to the treatment of cholera has been established by the reductions shown in total stool volume, duration of diarrhoea, and duration of detectable V. cholerae excretion following oral antibiotic administration.
Tetracycline (Greenough et al., 1964; Wallace et al., 1965; Carpenter et al., 1966) , chloramphenicol (Wallace et al., 1968; Lindenbaum et al., 1968) , and streptomycin (Lindenbaum et at., 1968) have been shown to be effective. However, the demonstration of rapidly developing resistance of V. cholerae to streptomycin seems to limit its usefulness as a therapeutic agent (Lewis, 1967) . Sulphaguanidine and paromomycin are of little or no value in the treatment of cholera (Lindenbaum et al., 1967; Wallace et al., 1968) . Tetracycline has been recommended as the antibiotic of choice in cholera (Wallace et al., 1968) .
Cholera vibrios (classical and El Tor biotypes) have been reported to be sensitive to furazolidone, and it has been suggested that this antibacterial agent is of value in the treatment of cholera (Chaudhuri et al., 1965 (Chaudhuri et al., , 1968 Kobari, 1965) . The present study confirms its effectiveness in cholera, indicating that furazolidone, in either dosage schedule used, reduced total stool volume by about 50% and duration of diarrhoea by about 40%, these results not differing significantly from those obtained with tetracycline given in the usually recommended dosage (4 g. total dose). The rates of decline in stool output after antibiotic therapy were also comparable with furazolidone and tetracycline, and with either drug were significantly greater than in controls. Furthermore, the time of onset of an effect on the rate of stool output was the same with furazolidone and tetracycline. With both agents a decrease in the rate of stool production attributable to antibiotic therapy was definitely present 18 to 24 hours after initiation of antibiotic treatment and may have begun as early as 6 to 12 hours after treatment. Recurrence of diarrhoea after termination of therapy was not noted with either antibiotic.
The results of treatment with tetracycline and furazolidone differed, however, in that detectable V. cholerae excretion was consistently reduced to less than two days with tetracycline but was only moderately reduced by furazolidone, lasting up to seven days in one patient. Prompt and consistent termination of V. cholerae excretion is a desired result of the antibiotic treatment of cholera, because it is possible that patients returning home still excreting cholera vibrios may contribute to further spread of the organisms in the community. Since the stay in hospital for treatment and control of the diarrhoea of cholera may usually be reduced to three days when effective antibiotic adjuncts are used, it is highly desirable that V. cholerae excretion be terminated within this period. This was accomplished with tetracycline but was not consistently achieved with furazolidone in either schedule used. We have therefore concluded that furazolidone is effective in the treatment of cholera but is inferior to tetracycline (when given in 4 g. total dosage) because of its failure to achieve a comparable and consistent reduction in the duration of V. cholerae excretion. Furazolidone appears to be comparable to tetracycline in regard to all other aspects of therapeutic effectiveness measured in this study.
The reliability of tetracycline in terminating V. cholerae excretion is borne out by our observations in 46 cholera patients during the past three years, which indicate that a total dose of 3-4 g. of tetracycline reduced vibrio excretion to a mean of 1.3 days and a maximum of three days. Lower doses of tetracycline (2 g. total dose) have, however, been associated with prolonged V. cholerae excretion in some patients and occasional relapse of diarrhoea (Wallace et al., 1965) .
Though not compared in this study, furazolidone appears to be as effective as chloramphenicol (Lindenbaum et al., 1967; Wallace et al., 1968) , which has been stated to be the alternative choice if tetracycline is not available or if clinically significant resistance of V. cholerae to tetracycline should occur (W.H.O., 1967) . Like furazolidone, chloramphenicol has been inconsistent in shortening V. cholerae excretion (Lindenbaum et al., 1967 (Lindenbaum et al., , 1968 , and occasional cases of prolonged excretion of cholerae vibrios after chloramphenicol have been reported (Gangarosa et al., 1966) . In comparison with chloramphenicol furazolidone has the advantage of both lower cost and greater safety. Furazolidone has not been associated with serious sideeffects, whereas hypoplastic anaemia is known to follow chloramphenicol administration occasionally.
The 22 strains of V. cholerae tested from the present study were inhibited and killed by moderate concentrations of tetracycline (2 to 8 ,ug./ml.). These figures indicate only a slight decrease in sensitivity of El Tor biotype strains to tetracycline when compared with those isolated in Calcutta in 1964 (Lewis and Sanyal, 1965) . Other reports indicate that significant resistance of cholera vibrios to tetracycline and chloramphenicol can be produced in vitro (Lewis, 1967) 16 ,ug./ml.) than of tetracycline, and that killing of cholera vibrios in 36% of strains tested did not occur with concentrations approaching the limit of solubility of the drug in intestinal fluid (40 1ug./ml.). This failure to effect killing of cholera vibrio strains within easily achieved antibiotic concentrations offers a possible explanation of the longer period of cholera vibrio excretion observed after furazolidone than after tetracycline treatment. It is of interest that comparable reductions in stool volume and duration of diarrhoea were achieved by antibacterial agents which differed significantly in their ability to terminate cholera vibrio excretion. It is possible that both agents rapidly reduce or inhibit the growth of the intestinal V. cholerae population and reduce the production of the cholera exotoxin responsible for the continuation of diarrhoea. However, tetracycline, which is vibriocidal, may rapidly carry this process to complete V. cholerae elimination, whereas furazolidone, which is not consistently vibriocidal in the concentrations probably achieved, may require host defence mechanisms to effect complete elimination of cholera vibrios.
Purging of convalescent cholera patients with magnesium sulphate has been used to detect prolonged carriers of cholera vibrios, which are not detectable by the culture of rectal swabs (Gangarosa et al., 1966; Wallace et al., 1967) . Of 43 patients so purged in this study one from the control group was idenfified as a convalescent carrier of cholera vibrios. In the past two years five such prolonged convalescent carriers have been identified by this unit (Wallace et al., 1967) . Three of these had received no antibiotic treatment, one had received initial treatment with furazolidone (200 mg. every six hours) for two days only (not included in this study), and one received tetracycline (500 mg. every six hours) for two days, beginning on the fourth day of illness. Though tetracycline (4 g. total dose) clearly shortens the duration of detectable V. cholerae excretion in most patients it is not yet certain that antibiotics reduce the incidence of the prolonged cholera vibrio carrier state detected in about 3 % of convalescent patients examined by this unit.
The large dosage of furazolidone used in this study was chosen to demonstrate maximal drug effect. The 1.2 g. schedule was as effective as the 2.4-g. schedule. It is probable that a schedule of 100 mg. every six hours for three days (1.2 g.) would be as effective as either schedule studied and might be associated with a lower incidence of vomiting, the only sideeffect noted.
